Escala Medical, a technology company that specializes in the treatment of the prolapse of the pelvic organ, has protected $ 4.5 million in financing.
EIC Fund led the round, which follows a subsidy of $ 2.9 million (€ 2.5 million) that was awarded to Escala in 2023 via the EIC Accelerator program.
What it does
The Escala Mendit product works to restore the function of the pelvic organ with the help of a technique that removes the need for tissue incision or dissection to connect the sacrospinous ligament with the vaginal wall.
The device has a navigation, anchoring and implementation mechanism. The tip of the applicator is led to the ligament with the help of the finger, where it then safely anchores the vaginal wall in the correct anatomical position.
According to the company, the procedure can be performed in an outpatient setting.
Escala will use the funds to expand its commercial activities in the US and to support its access to the European market. The company will also use the money to promote international growth through a signed distribution agreement with a partner based in Singapore.
“This financing marks an important milestone while we keep scaling our activities and bringing our breakthrough technology to more women worldwide,” said Edit Goldberg, CEO of Escala, in a statement.
“We are proud of having the support of the EIB and our private investors and we will continue to use the next generation of our Mendit device to improve the results and to expand access to millions of women worldwide that suffer from organ to the organ.”
Market Snapshot
Other companies in the pelvic health space include Origin, who will enter into a partnership in March with the TeleHealth Company of Ladies WISP to give their members access to each other’s services.
Hybrid care provider origin offers physiotherapy for the pelvic floor and the whole body to improve sexual health during pregnancy, postpartum and menopause.
WISP offers agreements on the same day for women looking for treatment for sexual and reproductive health instruments. Patients can make contact with a recognized medical care provider and, if necessary, obtain a recipe for personal pick-up or home delivery on the same day.
The company offers treatments for reproductive health, vaginal health, weight care, hormonal health and more.
Earlier this month, Sword Health raised $ 40 million and brought his total financing to $ 380 million and its appreciation of $ 4 billion. Sword used the funds to support its global expansion, further developed his AI models in various care areas and speeds up his momentum in mergers and acquisitions.
In 2024, Axena Health, which develops a digital therapeutic for women’s pelvic health, collaborated with the direct telehealth company upscripthealth to offer consultation and treatment to women who experience urinary incontinence symptoms.
Axena’s Leva pelvic health system helps women with pelvic floor muscle training (PFMT), an primary care treatment that can be completed at home.
In 2023, Axena Health has collected a series A investment of $ 25 million from XA im Alts.
Axena offers the Leva Pelk Health system, a digital therapeutic recipe aimed at the treatment of urine incontinence and chronic fecal incontinence in women.
The system, which has received FDA 510 (K) clearanceIncludes a vaginal motion sensor that connects to an app, accompanied users by pelvic floor muscle training.
According to a spokesperson for Axena, the company has taken over the system from Renovia, who developed and commercialized Leva before it was closed in 2022. Last year. Renovia had previously collected $ 17 million in series C-1 financing in 2021 and a series B of $ 32.3 million in 2018.
In 2022, digital musculoskeletale healthcare company Sword Health launched a women’s physiotherapy product aimed at pelvic health and pain.
The product, Bloom, includes a sensor that measures the pressure and endurance of the pelvic floor and connects to an app, allowing users to receive feedback on their exercises.
Members are linked to a pelvic health specialist who leads them through exercises and makes changes to their program based on their needs and results.
That same year, Hinge Health launched a ladies’ pelvic health program. The program of Hinge, available in the same platform as the rest of its musculoskeletal tools, offers educational content and access to a care team consisting of physiotherapists, health coaches for women and urogyna cologists.
Hinge Went public in May and raised $ 437.3 million in his first public offer. that sold 9.14 million shares. Hinge opened De Nyse against a share price of $ 39.25 per share, 23% higher than the IPO price of $ 32 originally expected.
The company Stock is now being traded for $ 51.80 per share.
#Escala #Medical #raises #million #medical #device #pelvic #organ